Flatulence News and Research

RSS
Flatulence is the expulsion through the rectum of a mixture of gases that are byproducts of the digestion process of mammals and other animals.
Shire, Janssen enter development and marketing agreement for Resolor

Shire, Janssen enter development and marketing agreement for Resolor

Shire acquires rights to develop and market Resolor in the U.S.

Shire acquires rights to develop and market Resolor in the U.S.

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Probiotics appear to protect against upper respiratory tract infections

Probiotics appear to protect against upper respiratory tract infections

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott’s CREON receives FDA approval for infant-specific dose

Abbott’s CREON receives FDA approval for infant-specific dose

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Devrom is effective for eliminating flatulence, stool odor issues

Devrom is effective for eliminating flatulence, stool odor issues

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Adjunctive lacosamide reduces seizures and improves responder rates

Adjunctive lacosamide reduces seizures and improves responder rates

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Patients with chronic constipation prefer Kristalose oral solution

Patients with chronic constipation prefer Kristalose oral solution